Spatiotemporal Control of IL-12 Delivery Improves Its Efficacy in Treatment of Solid Tumors

IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Jonathan C. Su, Garrett M. Kelly, Joshua J. Milligan, Sonal Deshpande, Rachel L. Strader, Max R. Ney, Nikhil Peterson, Parul Sirohi, Shaily Pal, Lance W. Lindsey, Daniel M. Shapiro, Xinghai Li, Ashutosh Chilkoti
{"title":"Spatiotemporal Control of IL-12 Delivery Improves Its Efficacy in Treatment of Solid Tumors","authors":"Jonathan C. Su,&nbsp;Garrett M. Kelly,&nbsp;Joshua J. Milligan,&nbsp;Sonal Deshpande,&nbsp;Rachel L. Strader,&nbsp;Max R. Ney,&nbsp;Nikhil Peterson,&nbsp;Parul Sirohi,&nbsp;Shaily Pal,&nbsp;Lance W. Lindsey,&nbsp;Daniel M. Shapiro,&nbsp;Xinghai Li,&nbsp;Ashutosh Chilkoti","doi":"10.1002/adtp.202500077","DOIUrl":null,"url":null,"abstract":"<p>Despite renewed interest in IL-12 as a cancer immunotherapy due to its ability to stimulate the adaptive immune system, its short half-life and narrow therapeutic window continues to present challenges for effective delivery. Previous studies with IL-12 have investigated the effects of route of delivery or sustained delivery of the cytokine on its efficacy but are unable to simultaneously investigate the effects of both within the same system. This work seeks to address this gap by utilizing an elastin-like polypeptide (ELP) carrier, which can undergo a thermally triggered phase transition to a gel-like depot, to probe the effects of both sustained release and spatial delivery of IL-12. By conjugating IL-12 with an ELP, this work creates an IL-12-ELP fusion that can be injected intratumorally or subcutaneously to form a sustained-release depot. In a B16F10 murine model, intratumoral injection of a depot-forming IL-12-ELP fusion significantly improved survival compared to free IL-12. IL-12-ELP is retained within the tumor approximately fourfold longer than free IL-12, resulting in higher CD8+ T cell recruitment at the tumor and local concentrations of inflammatory cytokines at Day 2. Taken together, this work provides insights into rational cytokine delivery, the importance of tumor localization, and the benefits of sustained release.</p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 8","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://advanced.onlinelibrary.wiley.com/doi/10.1002/adtp.202500077","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Despite renewed interest in IL-12 as a cancer immunotherapy due to its ability to stimulate the adaptive immune system, its short half-life and narrow therapeutic window continues to present challenges for effective delivery. Previous studies with IL-12 have investigated the effects of route of delivery or sustained delivery of the cytokine on its efficacy but are unable to simultaneously investigate the effects of both within the same system. This work seeks to address this gap by utilizing an elastin-like polypeptide (ELP) carrier, which can undergo a thermally triggered phase transition to a gel-like depot, to probe the effects of both sustained release and spatial delivery of IL-12. By conjugating IL-12 with an ELP, this work creates an IL-12-ELP fusion that can be injected intratumorally or subcutaneously to form a sustained-release depot. In a B16F10 murine model, intratumoral injection of a depot-forming IL-12-ELP fusion significantly improved survival compared to free IL-12. IL-12-ELP is retained within the tumor approximately fourfold longer than free IL-12, resulting in higher CD8+ T cell recruitment at the tumor and local concentrations of inflammatory cytokines at Day 2. Taken together, this work provides insights into rational cytokine delivery, the importance of tumor localization, and the benefits of sustained release.

Abstract Image

Abstract Image

Abstract Image

Abstract Image

时空控制IL-12的传递提高其治疗实体瘤的疗效
尽管由于IL-12刺激适应性免疫系统的能力,人们对IL-12作为一种癌症免疫疗法重新产生了兴趣,但其半衰期短和治疗窗口窄仍然是有效递送的挑战。先前对IL-12的研究已经研究了细胞因子的递送途径或持续递送对其疗效的影响,但无法同时研究同一系统内两者的影响。这项工作试图通过利用弹性蛋白样多肽(ELP)载体来解决这一空白,该载体可以经历热触发的相变到凝胶样储库,以探测IL-12的持续释放和空间递送的影响。通过将IL-12与ELP结合,这项工作创造了IL-12-ELP融合物,可以在瘤内或皮下注射形成一个缓释库。在B16F10小鼠模型中,与游离IL-12相比,瘤内注射沉积形成的IL-12- elp融合物显著提高了生存率。IL-12- elp在肿瘤内的保留时间大约是游离IL-12的四倍,导致肿瘤中CD8+ T细胞的募集增加,第2天炎症细胞因子的局部浓度增加。综上所述,这项工作为细胞因子的合理传递、肿瘤定位的重要性以及持续释放的益处提供了见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advanced Therapeutics
Advanced Therapeutics Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
7.10
自引率
2.20%
发文量
130
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信